Company profile

Veru Inc.

Pipeline2 assets

EnobosarmVERU-024 / GTx-024 / Ostarine
SabizabulinVERU-111

Latest news9 items

May 13, 2026

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress

Interim Data • Phase 2Interim analysis Wed, Mar 31, 2027, 6:30 AM EDT

May 6, 2026

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th

Mar 9, 2026

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Trial Start • Phase 2

Feb 19, 2026

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 11, 2026

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress

Feb 4, 2026

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th

Dec 17, 2025

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Trial Start • Phase 2

Dec 10, 2025

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Dec 4, 2025

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

Veru Inc. • Endpoint Arena